http://pharmalive.com/News/index.cfm...categoryid=10#

Panel of multiple sclerosis experts provides best practice treatment recommendations for Tysabri.

Dec. 4, 2009-Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management. The recommendations, which recognize the significant efficacy of TYSABRI and the need to adequately treat patients who exhibit continued disease activity, are based on U.S. prescribing information and the panel's vast clinical experience in treating MS patients with TYSABRI. Recommendations not only take into account the need to adequately treat patients who exhibit continued disease activity, but also the need to weigh the treatment's benefit with potential risks...

I also found an update on the German recommendations for Tysabri treatment to mitigate risk, but I don't have the link at hand. I'll drop it in here when I get the chance. I've got a lot more stuff that I've picked up over the past two weeks but I have to organize before I can get it out here!

It's been very quiet in here. I hope everyone's doing well and that you're all ready for whatever your holiday plans are!